

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During scope consultation, stakeholders identified the following potential equality issues:

- Disparate access to treatments and severe asthma centres, which increases health inequalities. Those on lowest incomes are most likely to have poorer outcomes, in part due to poorer access.
- Children or young people or those with a needle phobia may benefit more from depemokimab, as the administration method is less frequent than comparators (every 6 months, instead of fortnightly or monthly)
- In clinical trials, the number of patients aged 12 – 17 years old was very small and so the evidence is not robust. Many paediatric severe asthma clinicians question the assumption that efficacy and safety outcomes from adults can be generalised to adolescents.
- Due to the prolonged duration of action of depemokimab there may be implications for women of child-bearing potential

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider how its recommendations may have a differential impact on children and young people, people who may have difficulty accessing specialist treatment centres and those with needle phobias. The committee will consider the technology within the marketing authorisation.

The committee will consider any specific impact on women of child-bearing potential which results from the prolonged duration of action.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 10 June 2025